Biohaven Ltd. Share Price & Technical Analysis
BHVN · $9.45 (-0.32%)
Healthcare / Biotechnology
$9.45
-0.32%
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase …
Price chart
Seasonality
May has 1 positive and 3 negative years (last 5 years shown)
-3% return in May, -3% avg return in past 3 year May month.
-12% return in 2026, 23% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 4% | -1% | -25% | 14% | -3% | – | – | – | – | – | – | – | -12% |
| 25 | 1% | -1% | -35% | -8% | -33% | -5% | 8% | 3% | -2% | 15% | -32% | 14% | -75% |
| 24 | 6% | 7% | 15% | -29% | -9% | -3% | 13% | 1% | 28% | 1% | -8% | -19% | 3% |
| 23 | 35% | -20% | -10% | -4% | 34% | 31% | -17% | -7% | 41% | 2% | 26% | 29% | 140% |
| 22 | – | – | – | – | – | – | – | – | 5% | 168% | -7% | -13% | 154% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Uptrend
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.34B
P/E ratio
—
52W high
$18.57
52W low
$7.48
Volume
14,39,359
Beta
3.31
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Biohaven Ltd. share price today?
- Biohaven Ltd. (BHVN) last traded around $9.45 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does BHVN have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for BHVN. Download the app for real-time alerts.
- How can I analyze Biohaven Ltd. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.